Our Vision
We aim to be the world’s leading cancer gene therapy company, delivering medicines of value to patients with cancer.
Our Strategy
We focus on discovering and developing innovative gene-based immuno-oncology treatments for solid tumors using our proprietary intravenously administered T-SIGn virus platform. Our portfolio of differentiated gene therapy products are all delivered systemically but act locally within the tumor.
Our Values
We choose to fight cancer
alongside all of those patients who did not choose to be in that fight.
We choose to make a difference
because innovation and science can push the boundaries of what is possible.
We choose to work with honesty and integrity
because we recognise the important responsibilities that we have.
We choose to respect each other and our partners
because by working together we can achieve so much more than by working alone.
Comments are closed.